Accessibility Menu
Artiva Biotherapeutics logo

Artiva Biotherapeutics(NASDAQ) ARTV

Market Cap$522.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-10%
5 YearN/A
1 Year+280%
1 Month+12%
$10.79
+0.28%
+0.03Today
Artiva Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 10.762026-08-03
Artiva Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.26%USD 10.322026-07-27
1 month+11.97%USD 9.612026-07-02
3 month+1.51%USD 10.602026-05-05
Year to date+150.82%USD 4.292025-12-31
1 year+280.21%USD 2.832025-08-01
Since inception-10.33%USD 12.002024-07-19

Artiva Biotherapeutics Financials at a Glance

Market Cap

$522.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$87.07M

EPS (TTM)

-$3.55

P/E Ratio

-3.03

Dividend

$0.00

Beta (Volatility)

1.51 (High)

Price

$10.79

Volume

221,149.46

Open

$10.60

Previous Close

$10.76

Daily Range

$10.40 - $11.11

52-Week Range

$2.22 - $14.53

Estimated Earnings Date

Aug 5, 2026

ARTV News

Foolcom-Featured.png

Artiva (ARTV) Q2 Loss Widens 19.7%

Motley Fool Markets TeamAug 6, 2025
GettyImages-1496103634

This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment

Leo MillerAug 29, 2024

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Artiva Biotherapeutics

Artiva makes ready-to-use cell treatments for serious diseases. These therapies help people with joint pain and lupus. The goal is making treatments easier to get.

What Artiva Makes

  • AlloNK: Ready-to-use therapy using "natural killer" immune cells to treat joint pain and other autoimmune diseases.
  • AB-201: Experimental treatment that uses modified donor cells to find and kill specific cancer proteins.
  • AB-205: Drug candidate that helps reset the immune system by targeting a protein found on certain white blood cells.
  • Manufacturing Services: Dedicated production facility in San Diego that creates, freezes, and ships cell therapy batches to clinics.

Moving Toward the Market

  • Reached an agreement with the U.S. Food and Drug Administration (FDA) in May 2026 on the design for a large final-stage study.
  • Signed a deal with Leerink Partners in August 2025 to sell up to $12 million in stock to fund operations.
  • Partnered with GC Cell Corporation to license immune cell technology for use in most global markets outside of Asia.
  • Contracted with Blackbird Clinical and Carnot Pharma in 2024 to provide expert consulting for ongoing patient trials.

Why This Approach is Unique

Artiva uses a ready-to-use manufacturing process that creates large batches of frozen treatments from umbilical cord blood. Its in-house San Diego facility allows for direct control over complex production and cold chain delivery logistics.

Checking the Financial Pulse

  • Net loss reached $23.5 million in Q1 2026, up 15.8% from Q1 2025.
  • Research and development costs hit $19.3 million in Q1 2026, up from $17.1 million a year earlier.
  • Total cash and short-term investments were $86.8 million as of March 31, 2026.
  • Operating cash flow deficit was $20.9 million in Q1 2026, up 5.6% from Q1 2025.

Bottom Line

Artiva has evolved from a research firm into a developer of ready-to-use cell treatments for common autoimmune diseases. Its focus on in-house manufacturing and clinical testing for joint pain marks its current strategic direction.

AI Generated • May 13, 2026

Industry

Biotechnology

Sector

Health Care

Employees

104

CEO

Fred Aslan, MD, MBA

Website

www.artivabio.com

Headquarters

San Diego, CA 92121, US

ARTV Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-73.16%

Return on Capital

-74.94%

Return on Assets

-82.18%

Earnings Yield

-33.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$522.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

48.59M

Volume

221.15K

Avg. Volume

604.37K

Financials (TTM)

Gross Profit

-$666.00K

Operating Income

-$92.07M

EBITDA

-$84.44M

Operating Cash Flow

-$77.86M

Capital Expenditure

-$2.32M

Free Cash Flow

-$80.18M

Cash & ST Invst.

$86.78M

Total Debt

$10.26M

Artiva Biotherapeutics Performance Analysis

Artiva Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,931,000146.3%
20232023-12-31USD 33,492,000579.2%
20242024-12-31USD 251,000-99.3%
20252025-12-31USD 0N/A
Artiva Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Artiva Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.42-40.7%
20232023-12-31USD -1.18-51.1%
20242024-12-31USD -2.69127.6%
20252025-12-31USD -3.4327.5%
Artiva Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-4.8%
Q32025-09-30-1.1%
Q42025-12-313.4%
Q12026-03-31-11.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$666.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$522.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.03M

N/A

Employees

104

N/A

Net Income

-$23.52M

-15.8%

EBITDA

-$22.85M

-16.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$86.78M

-47.7%

Total Debt

$10.26M

-26.7%

Accounts Receivable

$600.00K

-42.0%

Inventory

$0.00

N/A

Long Term Debt

$7.23M

-29.7%

Short Term Debt

$3.04M

-18.4%

Return on Assets

-82.18%

N/A

Return on Invested Capital

-96.84%

N/A

Free Cash Flow

-$21.19M

-4.1%

Operating Cash Flow

-$20.95M

-5.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
STTKShattuck Labs, Inc.
$7.52+3.10%
ZNTLZentalis Pharmaceuticals, Inc.
$4.86+4.41%
ALXOALX Oncology Holdings Inc.
$1.99+2.85%
STROSutro Biopharma, Inc.
$25.72+2.48%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$160.94+0.28%
AMIXAutonomix Medical
$10.55+1.89%
NOKNokia
$9.99+0.07%
INTCIntel
$100.17+0.10%

Questions About ARTV

What is the current price of Artiva Biotherapeutics?

Artiva Biotherapeutics is trading at $10.90 per share.

What is the 52-week range for Artiva Biotherapeutics?

Over the past 52 weeks, Artiva Biotherapeutics has traded between $2.22 and $14.53.

How much debt does Artiva Biotherapeutics have?

As of the most recent reporting period, Artiva Biotherapeutics reported total debt of $10.26M.

How much cash does Artiva Biotherapeutics have on hand?

Artiva Biotherapeutics reported $20.96M in cash and cash equivalents in its most recent financial results.

What is Artiva Biotherapeutics’s dividend yield?

Artiva Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services